AstraZeneca (Moventig)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Drug for opioid-induced constipation (OIC) treatment. The portfolio consists of the rights to sell and develop Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Parent Company
Primary Office
- 2 Kingdom Street
- London W2 6BD
- England, United Kingdom
AstraZeneca (Moventig) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore AstraZeneca (Moventig)‘s full profile, request access.
Request full access to PitchBookAstraZeneca (Moventig) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore AstraZeneca (Moventig)‘s full profile, request access.
Request full access to PitchBook